Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant
- PMID: 35752196
- PMCID: PMC9221361
- DOI: 10.1016/S1473-3099(22)00409-1
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant
Conflict of interest statement
MMH reports research grants from WHO, Coalition for Epidemic Preparedness Innovations (CEPI), Asian Development Bank (ADB), Bill & Melinda Gates Foundation, and Pfizer (all paid to the institution). AB and KKW report research grants from WHO and CEPI paid to the institution. EE reports stock ownership in GlaxoSmithKline. MDK reports research grants from WHO, CEPI, ADB, and Pfizer (all paid to the institution) and consultancy fees from Merck. All other authors declare no competing interests. DRF and MDK contributed equally. All data included were derived from publicly available documents cited in the references. Extracted data are available on request to the corresponding author. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.
Figures
Similar articles
-
Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.PLoS Med. 2022 Sep 1;19(9):e1003992. doi: 10.1371/journal.pmed.1003992. eCollection 2022 Sep. PLoS Med. 2022. PMID: 36048766 Free PMC article.
-
Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.Front Immunol. 2022 Aug 24;13:940562. doi: 10.3389/fimmu.2022.940562. eCollection 2022. Front Immunol. 2022. PMID: 36091023 Free PMC article.
-
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.Front Public Health. 2022 Jul 13;10:940956. doi: 10.3389/fpubh.2022.940956. eCollection 2022. Front Public Health. 2022. PMID: 35910897 Free PMC article.
-
Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review.Hum Vaccin Immunother. 2022 Nov 30;18(5):2062983. doi: 10.1080/21645515.2022.2062983. Epub 2022 May 2. Hum Vaccin Immunother. 2022. PMID: 35499517 Free PMC article.
-
SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.J Infect. 2023 Dec;87(6):506-515. doi: 10.1016/j.jinf.2023.08.009. Epub 2023 Sep 28. J Infect. 2023. PMID: 37777159
Cited by
-
Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern.NPJ Vaccines. 2022 Oct 12;7(1):118. doi: 10.1038/s41541-022-00540-7. NPJ Vaccines. 2022. PMID: 36224247 Free PMC article.
-
Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines.Biomedicines. 2023 Jan 27;11(2):370. doi: 10.3390/biomedicines11020370. Biomedicines. 2023. PMID: 36830907 Free PMC article. Review.
-
Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study.EClinicalMedicine. 2023 Dec 13;67:102374. doi: 10.1016/j.eclinm.2023.102374. eCollection 2024 Jan. EClinicalMedicine. 2023. PMID: 38169940 Free PMC article.
-
Finally neutralizing the threat? A novel SARS-CoV-2 vaccine platform that elicits enhanced neutralizing antibody responses.mBio. 2024 Apr 10;15(4):e0006724. doi: 10.1128/mbio.00067-24. Epub 2024 Feb 26. mBio. 2024. PMID: 38407097 Free PMC article.
-
Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?Emerg Microbes Infect. 2023 Dec;12(1):2174779. doi: 10.1080/22221751.2023.2174779. Emerg Microbes Infect. 2023. PMID: 36715323 Free PMC article.
References
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical